Literature DB >> 30580918

Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.

Michael S Poslusney1, James M Salovich1, Michael R Wood1, Bruce J Melancon1, Katrina A Bollinger1, Vincent B Luscombe1, Alice L Rodriguez1, Darren W Engers1, Thomas M Bridges1, Colleen M Niswender2, P Jeffrey Conn2, Craig W Lindsley3.   

Abstract

This letter describes a focused exercise to explore the role of the β-amino carboxamide moiety found in all of the first generation M4 PAMs and question if the NH2 group served solely to stabilize an intramolecular hydrogen bond (IMHB) and enforce planarity. To address this issue (and to potentially find a substitute for the β-amino carboxamide that engendered P-gp and contributed to solubility liabilities), we removed the NH2, generating des-amino congeners and surveyed other functional groups in the β-position. These modifications led to weak M4 PAMs with poor DMPK properties. Cyclization of the β-amino carboxamide moiety by virtue of a pyrazole ring re-enforced the IMHB, led to potent (and patented) M4 PAMs, many as potent as the classical bicyclic β-amino carboxamide analogs, but with significant CYP1A2 inhibition. Overall, this exercise indicated that the β-amino carboxamide moiety most likely facilitates an IMHB, and is essential for M4 PAM activity within classical bicyclic M4 PAM scaffolds.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  M(4); Muscarinic acetylcholine receptor; Positive allosteric modulator (PAM); Structure-Activity Relationship (SAR); Tricycle

Mesh:

Substances:

Year:  2018        PMID: 30580918      PMCID: PMC6690489          DOI: 10.1016/j.bmcl.2018.12.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

1.  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.

Authors:  James C Tarr; Michael R Wood; Meredith J Noetzel; Bruce J Melancon; Atin Lamsal; Vincent B Luscombe; Alice L Rodriguez; Frank W Byers; Sichen Chang; Hyekyung P Cho; Darren W Engers; Carrie K Jones; Colleen M Niswender; Michael W Wood; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-10-24       Impact factor: 2.823

2.  Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100.

Authors:  Nellie E Byun; Michael Grannan; Michael Bubser; Robert L Barry; Analisa Thompson; John Rosanelli; Raajaram Gowrishankar; Nathaniel D Kelm; Stephen Damon; Thomas M Bridges; Bruce J Melancon; James C Tarr; John T Brogan; Malcolm J Avison; Ariel Y Deutch; Jürgen Wess; Michael R Wood; Craig W Lindsley; John C Gore; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2014-01-20       Impact factor: 7.853

3.  Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.

Authors:  Travis T Wager; Xinjun Hou; Patrick R Verhoest; Anabella Villalobos
Journal:  ACS Chem Neurosci       Date:  2016-04-04       Impact factor: 4.418

4.  Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.

Authors:  Madeline F Long; Julie L Engers; Sichen Chang; Xiaoyan Zhan; Rebecca L Weiner; Vincent B Luscombe; Alice L Rodriguez; Hyekyung P Cho; Colleen M Niswender; Thomas M Bridges; P Jeffrey Conn; Darren W Engers; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-10-09       Impact factor: 2.823

5.  Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.

Authors:  Michael R Wood; Meredith J Noetzel; Michael S Poslusney; Bruce J Melancon; James C Tarr; Atin Lamsal; Sichen Chang; Vincent B Luscombe; Rebecca L Weiner; Hyekyung P Cho; Michael Bubser; Carrie K Jones; Colleen M Niswender; Michael W Wood; Darren W Engers; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-11-30       Impact factor: 2.823

6.  Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154.

Authors:  Robert W Gould; Michael D Grannan; Barak W Gunter; Jacob Ball; Michael Bubser; Thomas M Bridges; Jurgen Wess; Michael W Wood; Nicholas J Brandon; Mark E Duggan; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2017-07-17       Impact factor: 5.250

7.  Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Authors:  W Y Chan; D L McKinzie; S Bose; S N Mitchell; J M Witkin; R C Thompson; A Christopoulos; S Lazareno; N J M Birdsall; F P Bymaster; C C Felder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

8.  Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.

Authors:  Michael R Wood; Meredith J Noetzel; Julie L Engers; Katrina A Bollinger; Bruce J Melancon; James C Tarr; Changho Han; Mary West; Alison R Gregro; Atin Lamsal; Sichen Chang; Sonia Ajmera; Emery Smith; Peter Chase; Peter S Hodder; Michael Bubser; Carrie K Jones; Corey R Hopkins; Kyle A Emmitte; Colleen M Niswender; Michael W Wood; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-05-05       Impact factor: 2.823

9.  Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.

Authors:  Mark S Moehle; Tristano Pancani; Nellie Byun; Samantha E Yohn; George H Wilson; Johnathan W Dickerson; Daniel H Remke; Zixiu Xiang; Colleen M Niswender; Jürgen Wess; Carrie K Jones; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuron       Date:  2017-12-20       Impact factor: 17.173

10.  Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.

Authors:  Ashley E Brady; Carrie K Jones; Thomas M Bridges; J Phillip Kennedy; Analisa D Thompson; Justin U Heiman; Micah L Breininger; Patrick R Gentry; Huiyong Yin; Satyawan B Jadhav; Jana K Shirey; P Jeffrey Conn; Craig W Lindsley
Journal:  J Pharmacol Exp Ther       Date:  2008-09-04       Impact factor: 4.030

View more
  2 in total

1.  SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs.

Authors:  Trevor C Chopko; Changho Han; Alison R Gregro; Darren W Engers; Andrew S Felts; Mike S Poslusney; Katrina A Bollinger; Ryan D Morrison; Michael Bubser; Atin Lamsal; Vincent B Luscombe; Hyekyung P Cho; Nathalie C Schnetz-Boutaud; Alice L Rodriguez; Sichen Chang; J Scott Daniels; Donald F Stec; Colleen M Niswender; Carrie K Jones; Michael R Wood; Michael W Wood; Mark E Duggan; Nicholas J Brandon; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley; Bruce J Melancon
Journal:  Bioorg Med Chem Lett       Date:  2019-06-20       Impact factor: 2.823

Review 2.  Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias.

Authors:  Emma T van der Westhuizen; K H Christopher Choy; Celine Valant; Simon McKenzie-Nickson; Sophie J Bradley; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.